---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-286918"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-06-29T12:32:15+00:00"
generated_at: "2026-06-29T12:35:09.166845+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication

## Summary
- Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.
- Company will cease EVO756 development for CSU but will continue evaluation in atopic dermatitis and migraine.
- Top-line Phase 2b data for EVO756 in atopic dermatitis expected Q3 2026; migraine trial screening initiated.
- Cash position supports anticipated operations through 2028; EVO301 Phase 2b for AD in planning.

## SEC filing metadata
- accession: 0001193125-26-286918
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-06-29T12:32:15+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/0001193125-26-286918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/evmn-20260629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-286918
- JSON: https://secwatch.observer/filing/0001193125-26-286918.json
- Plain text: https://secwatch.observer/filing/0001193125-26-286918.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.